Patients with central nervous system (CNS) disease are not eligible AML patients with active central nervous system (CNS) disease will be excluded. Active extramedullary AML in testes or central nervous system (CNS) Non-central nervous system (CNS) radiotherapy within week prior to CD of study therapy History or evidence of uncontrollable central nervous system (CNS) disease Subject has known current central nervous system (CNS) disease Presence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal) History of central nervous system (CNS) disease is acceptable if effectively treated and demonstrated stable disease for >= months from protocol tissue procurement Active central nervous system (CNS) disease at time of screening. Patients with primary central nervous system (CNS) cancer. Active central nervous system (CNS) disease. Central nervous system (CNS) tumors Central nervous system (CNS) disease Active extramedullary AML in testes or central nervous system (CNS) Patients with retinoblastoma protein (Rb) positive recurrent, progressive or refractory central nervous system (CNS) tumors Uncontrolled metastatic disease to the brain or central nervous system (CNS). Presence of central nervous system (CNS) disease, which is symptomatic TREATMENT WITH SJCAR: Central nervous system (CNS)- disease with or without neurologic changes Adequate central nervous system (CNS) function defined as:\r\n* Patients with seizure disorder may be enrolled if on allowed anti-convulsants and well controlled; benzodiazepines and gabapentin are acceptable\r\n* CNS toxicity < grade Patients must not have evidence of active central nervous system (CNS) disease Active central nervous system (CNS) or extramedullary disease Subjects with symptomatic central nervous system (CNS) disease which is not adequately controlled Uncontrolled central nervous system (CNS) disease (for hematologic malignancies) Have central nervous system disease (CNS) as follows: Active central nervous system (CNS) disease Patients with a history of central nervous system disease must have no clinical or radiological evidence of central nervous system (CNS) disease at the time of protocol enrollment and with CNS toxicity =< grade ; patients with seizure disorders may be enrolled if seizures are well controlled Presence of active and clinically relevant central nervous system (CNS) disorder; Presence of active and clinically relevant Central Nervous System (CNS) disorder (Bevacizumab-related exclusion) History or evidence upon physical/neurological examination of central nervous system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy Active central nervous system (CNS) disorder or seizure disorder or known CNS disease or neurologic symptomatology Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance; Active central nervous system (CNS) disease in patient with history of CNS malignancy. Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI) Active, uncontrolled central nervous system (CNS) disease Active central nervous system (CNS) malignancy Patients with history of central nervous system (CNS) lymphoma can be enrolled if the CNS disease has been controlled with therapy for a minimum of weeks; brain magnetic resonance imaging (MRI) is not required for eligibility Eligible for extra-central nervous system (CNS) SAbR to - sites of disease Active central nervous system (CNS) disease in patient with history of CNS malignancy Patients with clinical evidences of active central nervous system (CNS) disease at inclusion Active central nervous system (CNS) disease Patients with >= white blood cells in the cerebrospinal fluid with blasts (CNS) disease will be eligible if central nervous system (CNS) disease is responsive to therapy Patient with active central nervous system (CNS) disease Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least weeks after therapy Participant has overt central nervous system (CNS) disease (CNS status) Patients with a history of central nervous system disease must not have severe peripheral neuropathy, signs of leukencephalopathy, or active central nervous system (CNS) infection; patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed Patients with active central nervous system (CNS) or epidural tumor Patients with central nervous system (CNS) disease who have received treatment and disease has been stable for four weeks are eligible Active central nervous system (CNS) or extramedullary disease Active central nervous system (CNS) disease. Patients with central nervous system (CNS) tumors who are receiving steroids are eligible Non-central nervous system (CNS) radiotherapy within week prior to CD of study therapy No active central nervous system (CNS) disease Patients with active central nervous system (CNS) disease Patients may NOT have evidence or symptoms of central nervous system (CNS) disease at the time of enrollment Known chronic or active viral infections of the central nervous system (CNS) Confirmed absence of central nervous system (CNS) disease Active central nervous system (CNS) disease Patients with active central nervous system (CNS) disease Prior history of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease Patients with active central nervous system (CNS) or epidural tumor Patients with central nervous system (CNS) disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapy History of primary central nervous system (CNS) disease that would interfere with subject evaluation Patients who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible Patient with active central nervous system (CNS) disease No current central nervous system (CNS) myeloma at time of enrollment Tumors arising outside of the central nervous system (CNS) Presence of central nervous system (CNS) disease Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration Patients with central nervous system (CNS) malignancies. Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease. Active central nervous system (CNS) disease in patient with history of CNS malignancy Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy) Active central nervous system (CNS) disease Who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible Active leukemic central nervous system (CNS) disease Eligible for extra-central nervous system (CNS) SABR to - sites of disease Patients with active or untreated central nervous system (CNS) disease; patients previously treated for CNS disease must be asymptomatic and must not be using steroids for at least weeks prior to starting the study treatment Subject has known current central nervous system (CNS) disease Pre-existing central nervous system (CNS) demyelination or seizure disorders Central nervous system (CNS) toxicity =< grade Patients with active central nervous system (CNS) malignancy Central nervous system (CNS) function defined as:\r\n* Patients with seizure disorder may be enrolled if on allowed anti-convulsants and well controlled; benzodiazepines and gabapentin are acceptable\r\n* CNS toxicity =< grade Patient has chronic or active viral infections of the central nervous system (CNS) Patients with disease progression in the central nervous system (CNS) only Known active central nervous system (CNS) leukemia or lymphoma patients with previously treated CNS disease are permitted if neurologically stable with no ongoing or anticipated need for steroid therapy are eligible Patients with active central nervous system (CNS) or epidural tumor History of central nervous system (CNS) disease Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy Primary disease involving the Central Nervous System (CNS) Symptomatic leukoencephalopathy, active central nervous system (CNS) malignancy or other neuropsychiatric abnormalities believed to preclude transplantation Have symptomatic or non stable central nervous system (CNS) malignancy. History of or active central nervous system (CNS) malignancy Active/symptoms of central nervous system (CNS) disease Evidence for central nervous system (CNS) metastatic disease History or evidence upon physical/neurological examination of central nervous system (CNS) disease unrelated to cancer, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures) Patient has active or history of central nervous system (CNS) disease Adequate central nervous system function defined as:\r\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\r\n* CNS toxicity =< grade Active central nervous system (CNS) disease at the time of treatment Active central nervous system (CNS) or symptomatic epidural metastatic disease History of central nervous system (CNS) lymphoma or other CNS disease No active central nervous system (CNS) disease Known central nervous system (CNS) disease Patients with known active central nervous system (CNS) disease History of central nervous system (CNS) thrombotic/embolic or ischemic event(s) Symptomatic central nervous system (CNS) NHL. Symptomatic central nervous system (CNS) disease. Known active central nervous system (CNS) malignancy Known history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease). Hematologic and primary central nervous system (CNS) malignancies Any primary or active central nervous system (CNS) malignancy, including metastatic disease Presence of central nervous system (CNS) metastatic disease Active central nervous system (CNS) disease Patients with stable, treated central nervous system (CNS) disease are eligible Have active Central Nervous System (CNS) disease Active central nervous system (CNS) disease in patient with history of CNS malignancy Central Nervous System (CNS) disease only. Active central nervous system (CNS) disease Active central nervous system (CNS) or extramedullary malignant disease Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy Patients with central nervous system (CNS) disease or testicular disease are eligible Uncontrolled central nervous system (CNS) disease Known central nervous system (CNS) disease Patients with active central nervous system (CNS) malignancy are not eligible for this trial Active/symptoms of central nervous system (CNS) disease Central nervous system (CNS) disease Active central nervous system (CNS) disease in patient with history of CNS malignancy Patients with documented central nervous system (CNS) disease Patients with active central nervous system (CNS) disease Patients with a history of central nervous system (CNS) malignancy. Symptomatic or untreated central nervous system (CNS) metastatic disease. Patients with previously treated CNS metastatic disease which has been stable for at least days are eligible Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting Patient has active or history of central nervous system (CNS) disease. History of central nervous system (CNS) PTLD Active Central Nervous System [CNS] disease Active central nervous system (CNS) disease b. Central nervous system (CNS) trauma or active seizure disorders requiring medication Patients with active central nervous system (CNS) disease Pre-existing central nervous system (CNS) demyelination or seizure disorders Active MM involving the central nervous system (CNS). Active central nervous system (CNS) disease (related to primary malignancy) at the time of enrollment History of significant central nervous system (CNS) injury or disease predating or unrelated to cancer diagnosis Patient has symptomatic primary or metastatic central nervous system (CNS) disease Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy Patients with history of seizures or uncontrolled central nervous system (CNS) disease, significant hepatic or renal dysfunction Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy. History of central nervous system (CNS) tumor Cranial radiotherapy for central nervous system (CNS) leukostasis; History of Grade >= central nervous system (CNS) hemorrhage All patients need to have received at least one prior central nervous system (CNS) directed therapy; there is no restriction on the number of recurrences Participant is currently receiving treatment with benzodiazepines or other central nervous system (CNS) depressants Active central nervous system (CNS) disease History of central nervous system (CNS) disease, CNS radiation, intrathecal therapy, or CNS surgery Active central nervous system (CNS) disease (the action for acupuncture may be associated with central nervous system activity, and patients with CNS pathology may respond differently to treatment than the general population) Exclusion criteria include previous central nervous system (CNS) radiation or CNS tumors that in the judgment of the investigators are likely to undergo progression during or shortly after radiotherapy Uncontrolled central nervous system (CNS) disease (for hematologic malignancies) Non-central nervous system (CNS) malignant disease must be sufficiently controlled so that patient can be without additional systemic therapy for approximately months Central nervous system (CNS) only disease on recent imaging Patients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic. Suspected central nervous system (CNS) tumor(s) or sarcoma.